Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 2 (2007), Issue 9 (September)

1. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience.
   Dig Dis Sci, 52(10): 2472-7. [Abstract] [Full-text]
2. The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies.
   Dig Dis Sci, 52(10): 2576-9. [Abstract] [Full-text]
3. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
   Dig Dis Sci, 52(10): 2557-63. [Abstract] [Full-text]
4. Positive CAGE screen correlates with cirrhosis in veterans with chronic hepatitis C.
   Dig Dis Sci, 52(10): 2564-9. [Abstract] [Full-text]
5. Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.
   Dig Dis Sci, 52(10): 2540-9. [Abstract] [Full-text]
6. Platelet-activating factor inactivator (rPAF-AH) enhances liver's recovery after paracetamol intoxication.
   Dig Dis Sci, 52(10): 2580-90. [Abstract] [Full-text]
7. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection.
   Dig Dis Sci, 52(10): 2531-9. [Abstract] [Full-text]
8. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
   Dig Dis Sci, 52(10): 2525-30. [Abstract] [Full-text]
9. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease?
   Dig Dis Sci, 52(10): 2550-6. [Abstract] [Full-text]
10. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Dig Dis Sci, 52(10): 2497-500. [Abstract] [Full-text]
11. Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates.
    Dig Dis Sci, 52(10): 2501-7. [Abstract] [Full-text]
12. A Rift Valley fever atlas for Africa.
    Prev Vet Med, 82(1): 72-82. [Abstract] [Full-text]
13. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Int J Drug Policy, 18(5): 447-51. [Abstract] [Full-text]
14. The Jailbreak Health Project--incorporating a unique radio programme for prisoners.
    Int J Drug Policy, 18(5): 444-6. [Abstract] [Full-text]
15. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Int J Drug Policy, 18(5): 437-43. [Abstract] [Full-text]
16. Improving access to HCV treatment: external jugular venepuncture can overcome problems with difficult venous access.
    Int J Drug Policy, 18(5): 433-6. [Abstract] [Full-text]
17. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Int J Drug Policy, 18(5): 426-32. [Abstract] [Full-text]
18. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Int J Drug Policy, 18(5): 417-25. [Abstract] [Full-text]
19. Education by peers is the key to success.
    Int J Drug Policy, 18(5): 411-6. [Abstract] [Full-text]
20. Integrating HCV services for drug users: a model to improve engagement and outcomes.
    Int J Drug Policy, 18(5): 406-10. [Abstract] [Full-text]
21. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montréal.
    Int J Drug Policy, 18(5): 397-405. [Abstract] [Full-text]
22. Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.
    Int J Drug Policy, 18(5): 388-96. [Abstract] [Full-text]
23. Prejudice among health care workers toward injecting drug users with hepatitis C: does greater contact lead to less prejudice?
    Int J Drug Policy, 18(5): 381-7. [Abstract] [Full-text]
24. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Int J Drug Policy, 18(5): 374-80. [Abstract] [Full-text]
25. The depiction of stigmatization in research about hepatitis C.
    Int J Drug Policy, 18(5): 364-73. [Abstract] [Full-text]
26. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran.
    Int J Drug Policy, 18(5): 359-63. [Abstract] [Full-text]
27. Global estimates of prevalence of HCV infection among injecting drug users.
    Int J Drug Policy, 18(5): 352-8. [Abstract] [Full-text]
28. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.
    Int J Drug Policy, 18(5): 341-51. [Abstract] [Full-text]
29. How can hepatitis C be prevented in the long term?
    Int J Drug Policy, 18(5): 338-40. [Abstract] [Full-text]
30. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.
    J Virol, 81(19): 10614-24. [Abstract] [Full-text]
31. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.
    J Virol, 81(19): 10597-605. [Abstract] [Full-text]
32. Periportal and sinusoidal liver dendritic cells suppressing T helper type 1-mediated hepatitis.
    Gut, 56(10): 1445-51. [Abstract] [Full-text]
33. Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa.
    J Gen Virol, 88: 2686-95. [Abstract] [Full-text]
34. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence.
    Transplantation, 84(5): 650-4. [Abstract] [Full-text]
35. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation.
    Transplantation, 84(5): 587-91. [Abstract] [Full-text]
36. Identification of interspecies recombination among hepadnaviruses infecting cross-species hosts.
    J Med Virol, 79(11): 1741-50. [Abstract] [Full-text]
37. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
    J Med Virol, 79(11): 1655-63. [Abstract] [Full-text]
38. High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users.
    J Med Virol, 79(11): 1674-8. [Abstract] [Full-text]
39. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    J Med Virol, 79(11): 1650-4. [Abstract] [Full-text]
40. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    J Med Virol, 79(11): 1686-95. [Abstract] [Full-text]
41. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    J Med Virol, 79(11): 1664-70. [Abstract] [Full-text]
42. Characterization of hepatitis E virus from outbreak and sporadic cases in Turkmenistan.
    J Med Virol, 79(11): 1696-702. [Abstract] [Full-text]
43. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    J Med Virol, 79(11): 1671-3. [Abstract] [Full-text]
44. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients.
    J Med Virol, 79(11): 1679-85. [Abstract] [Full-text]
45. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.
    Clin Infect Dis, 45(8): 969-74. [Abstract] [Full-text]
46. Long-term outcome in children with chronic hepatitis B: a 24-year observation period.
    Clin Infect Dis, 45(8): 943-9. [Abstract] [Full-text]
47. 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease.
    AJR Am J Roentgenol, 189(4): 819-23. [Abstract] [Full-text]
48. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients.
    Clin Chem, 53(10): 1792-9. [Abstract] [Full-text]
49. Oral aloe vera-induced hepatitis.
    Ann Pharmacother, 41(10): 1740-3. [Abstract] [Full-text]
50. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers.
    Virology, 367(1): 30-40. [Abstract] [Full-text]
51. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
    Intern Med J, 37(10): 705-12. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.